Market Overview

UPDATE: Piper Jaffray Upgrades Osiris Therapeutics to Overweight on Strong Biosurgery Growth

Related OSIR
Earnings Scheduled For March 5, 2014
Journal Publishes Grafix Clinical Study for Chronic Wounds

Piper Jaffray upgraded Osiris Therapeutics (NASDAQ: OSIR) from Neutral to Overweight and maintained a $11.50 price target.

Piper Jaffray commented, "Osiris is blowing the doors off Biosurgery sales: up 284% yr/yr and 36% sequentially to $2.9 million in 4Q:12 and totaling $7.8 million for 2012. We now forecast Biosurgery sales growth of 123% to $17.5 million this year. Based on this robust growth, we are upgrading Osiris to Overweight and maintaining our $11.50 price target. Keep in mind that Osiris regained full rights to Prochymal from Genzyme/Sanofi and is now free to sign a new global licensing partnership."

Osiris Therapeutics closed at $6.91 on Tuesday.

Posted-In: Piper JaffrayAnalyst Color Upgrades Analyst Ratings

 

Most Popular

Related Articles (OSIR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free